INDEMNIFICATION AGREEMENTIndemnification Agreement • November 6th, 2013 • Tetralogic Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of November , 2013 by and between TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement, including without limitation the Indemnification Agreement, dated between the Company and the Indemnitee (the “Prior Agreement”)
TetraLogic Pharmaceuticals Corporation Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • November 6th, 2013 • Tetralogic Pharmaceuticals Corp • Pharmaceutical preparations • New York
TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as representatives (the “Representatives”) an aggregate of shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto. The Company also proposes to sell, at the Underwriters’ option, an aggregate of up to additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below.
THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 6th, 2013 • Tetralogic Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Third Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of , 2013, among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), those stockholders of the Company listed on Exhibit A hereto (individually, a “Common Stockholder,” and collectively, the “Common Stockholders”), and the stockholders listed on Exhibit B hereto (individually, an “Investor” and collectively, the “Investors”).
AMENDMENT NO. 1 TO WARRANT TO PURCHASE EQUITY SECURITIES OF TETRALOGIC PHARMACEUTICALS CORPORATIONWarrant to Purchase Equity Securities • November 6th, 2013 • Tetralogic Pharmaceuticals Corp • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (this “Amendment”), effective as of the day of October 2013, by and between TETRALOGIC PHARMACEUTICALS CORPORATION, a Delaware corporation (the “Company”), and [WARRANT HOLDER] (the “Holder”), amends certain warrants issued to Holder pursuant to that certain Note and Warrant Purchase Agreement dated by and among the Company and the Purchasers (as defined therein) and that certain Note and Warrant Purchase Agreement dated by and among the Company and the Purchasers (as defined therein) (each of the warrants issued under such purchase agreements are referred to as a “Warrant” and collectively, the “Warrants”). All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrants.
